Welcome to Accelerated — here's what to expect

Ryan BethencourtNov 4, 2026

Hey,

Welcome to Accelerated. I'm glad you're here.

Every week — Tuesday or Wednesday morning — I send one issue covering the frontier of longevity science and AI. Not summaries. Not press release rewrites. The actual thinking.

Here's what a typical issue looks like:

→ A lead story — one big idea explained properly, with primary sources. A clinical trial result, a new model capability, or a scientific finding most people missed.

→ Longevity briefing — 2–3 short dispatches on the most important longevity research from the past week. Senolytics, NAD+ biology, epigenetic reprogramming, the GLP-1 frontier.

→ AI briefing — what's actually moving in AI, with a focus on biotech applications. New models, new capabilities, what's being deployed in real clinical and research settings.

→ The Intersection — where AI and longevity collide. This is the part I'm most excited about, and it's moving faster than almost anyone appreciates.

→ Links — 5–7 things worth reading, watching, or following. No filler.

One ask: if anything resonates — or something's missing — hit reply and tell me. I read every response.

— Ryan

Ryan Bethencourt is a biotech founder and investor. Co-founder of IndieBio, the world's most prolific biotech seed accelerator. 180+ investments at the frontier of longevity, food tech, and biomaterials.

Private podcast setup:
To set up your podcast app, click this link on your phone.